vendredi 22 décembre 2017

Onco Actu du 22 décembre 2017

Pour info : Onco Actu interrompt sa parution pendant 2 semaines. 
Rendez-vous en 2018 !

1. Biologie

Roswell Park Research Identifies Cells that May be Responsible for Prostate Cancer Recurrence [Roswell Park Cancer Institute]

3.1 Prévention - Tabac

Nicotine patches and medications aren’t enough to quit smoking, a study finds [Stanford Medicine]

3.3 Prévention - Vaccins

HPV vaccine doesn’t lead to unsafe sex [Reuters]

4. Dépistage, diagnostic et pronostic

Is more screening a good thing? A Boston Global Health chat with researcher and author Dr. H. Gilbert Welch [Boston Global]

4.10 Dép., diag. & prono. - FDA, EMA, NICE,...

Genomic Profiling Tests Cleared by FDA Can Help Guide Cancer Treatment, Clinical Trial Enrollment [NCI]

4.9 Dép., diag. & prono. - Sein

New Genome Scores Predict Breast Cancer Odds for Any Woman [MIT Technology Review]

5. Traitements

PheWAS and FinnGen [Plenge Gen]

5.12 Immunothérapies

New technique could reveal immunotherapy targets [Stanford Medicine]

Cancer immunotherapy [Nature Outlook]

5.12.2 Immunothérapies - CAR-T

Janssen Enters Worldwide Collaboration and License Agreement with Chinese Company Legend Biotech to Develop Investigational CAR-T Anti-Cancer Therapy [Janssen]

J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO [EndPoints]

5.12.8 Immunothérapies - Economie

Celgene, GV-backed FLX gets off $60M round, kick-starts I-O trials [FierceBiotech]

Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price [EndPoints]

Google backs a $60M transition round for FLX’s switch to a CCR4 strategy [EndPoints]

5.2 Pharma

Absent From Cancer Drugs, Glaxo Signals a Revival With New Hire [Bloomberg]

Novartis' combination therapy Tafinlar® + Mekinist® granted FDA Priority Review for the adjuvant treatment of stage III BRAF V600 mutation-positive melanoma [Novartis]

U.S. FDA Grants Priority Review to Janssen for Apalutamide as a Treatment for Non-Metastatic Castration-Resistant Prostate Cancer [Janssen]

Novartis combo therapy for melanoma gets FDA priority review [Reuters]

5.2.2 Pharma - Fusions & Acquisitions

Roche splashes $1.7B in cash for Ignyta and entrectinib [FierceBiotech]

Roche to buy U.S. cancer drugmaker Ignyta for $1.7 billion [Reuters]

Roche and Ignyta reach definitive merger agreement [Roche]

5.3.4 Traitements - AMM (FDA, EMA)

5 Milestones Of 2017 In The War On Cancer [Forbes]

5.4 Traitements - Economie

NICE rejects Roche’s Tecentriq for pre-treated urothelial cancer [PharmaTimes]

6. Lutte contre les cancers

New NCI director expects big data to revolutionize cancer research, care [Science]

6.11 Patients

Living With Cancer: Immortality at Midnight [NY Times]

6.7 DMP, Big Data & applis

Deal struck to mine cancer patient database for new treatment insights [STAT]

Artificial intelligence in health care: within touching distance [The Lancet]

6.7.2 Applis

Accenture and Roche Collaborate to Enhance Digital Healthcare for Cancer Patients [Accenture]

Smartphone App Shows Promise Monitoring Chemotherapy Patients [University of Pittsburgh]